CORTEX PHARMACEUTICALS INC/DE/

Form 5

February 07, 2007

FORM 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL

OMB 3235-0362 Number:

January 31, Expires: 2005

Estimated average burden hours per

response... 1.0

no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction

Check this box if

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Form 3 Holdings Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

Reported Form 4

1(b).

30(h) of the Investment Company Act of 1940

Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL

OWNERSHIP OF SECURITIES

Transactions Reported

1. Name and Address of Reporting Person * 2. Issuer Name and Ticker or Trading 5. Relationship of Reporting Person(s) to Issuer ROGERS GARY ALLEN Symbol **CORTEX PHARMACEUTICALS** (Check all applicable) INC/DE/ [COR] (Middle) 3. Statement for Issuer's Fiscal Year Ended (Last) (First) Director 10% Owner _ Officer (give title Other (specify X (Month/Day/Year) below) below) 12/31/2006 Sr VP, Pharmaceutical Research 15241 BARRANCA PKWY (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Reporting Filed(Month/Day/Year) (check applicable line) IRVINE, CAÂ 92618 _X_ Form Filed by One Reporting Person Form Filed by More than One Reporting (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of 2. Transaction Date 2A. Deemed 3. 4. Securities 5. Amount of 6. Ownership 7. Nature of Security (Month/Day/Year) Execution Date, if Transaction Acquired (A) or Securities Form: Direct Indirect (Instr. 3) Code Disposed of (D) Beneficially (D) or Beneficial (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Owned at end Indirect (I) Ownership of Issuer's (Instr. 4) (Instr. 4) (A) Fiscal Year or (Instr. 3 and 4) Amount (D) Price **SEC 2270** Persons who respond to the collection of information Reminder: Report on a separate line for each class of contained in this form are not required to respond unless securities beneficially owned directly or indirectly. (9-02)the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount o
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	Derivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A)		

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 5

	Derivative Security				or Dispose (D) (Instr. 3, 4 and 5)					
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Options to Purchase Common Stock	\$ 3	09/05/2000	Â	A4	3,399	Â	(1)	09/05/2010	Common Stock	3,399
Options to Purchase Common Stock	\$ 0.75	12/16/2002	Â	A4	5,000	Â	(2)	12/16/2012	Common Stock	5,000
Options to Purchase Common Stock	\$ 2.76	12/09/2003	Â	A4	10,000	Â	(3)	12/09/2013	Common Stock	10,000
Options to Purchase Common Stock	\$ 2.68	12/16/2004	Â	A4	10,000	Â	(4)	12/16/2014	Common Stock	10,000
Options to Purchase Common Stock	\$ 2.35	12/01/2005	Â	A4	15,000	Â	(5)	12/01/2015	Common Stock	15,000
Options to Purchase Common Stock	\$ 1.3	12/18/2006	Â	A4	15,000	Â	(6)	12/18/2016	Common Stock	15,000

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
ROGERS GARY ALLEN 15241 BARRANCA PKWY IRVINE, CA 92618	Â	Â	Sr VP, Pharmaceutical Research	Â	

Reporting Owners 2

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 5

Signatures

Maria S. Messinger, Attorney in fact 02/07/2007

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option became fully vested and exercisable as of September 5, 2003.
- (2) The option became fully vested and exercisable as of December 16, 2005.
- (3) The option became fully vested and exercisable as of December 9, 2006.
- (4) The option becomes vested and exercisable in three equal annual installments beginning on December 16, 2005.
- (5) The option becomes vested and exerciable in three equal annual installments beginning on December 1, 2006.
- (6) The option becomes vested and exercisable in three equal annual installments beginning on December 18, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3